Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
https://doi.org/10.14341/omet201623-6
Abstract
Recently, the bihormonal theory of the autoimmune diabetes development is discussed in the world literature. The abnormal suppression of glucagon and reduced incretin response are considered in the development and progression of type 1 diabetes mellitus in addition to insulin deficiency. Animal studies demonstrate a GLP-1 – role in beta cell-proliferation and decrease in apoptosis. The information concerning the functioning of the incretin system in patients with type 1 diabetes and LADA is systematized in the present review. We also discuss the studies of the use of GLP-1 agonists in patients with autoimmune diabetes.
About the Authors
Iuliia V. Silko
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
Russian Federation
PhD
Competing Interests:
No conflict of interest
Tatiana V. Nikonova
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
Russian Federation
PhD
Competing Interests:
No conflict of interest
Marina V. Shestakova
Endocrinology Research Centre
Russian Federation
PhD
Competing Interests:
Russian Federation
PhD
Competing Interests:
No conflict of interest
References
1. Шестакова М.В. Роль аналога человеческого глюкагоноподобногопептида-1 в терапии сахарного диабета 2 типа // Сахарный диабет. – 2010. – Т. 13. – №3 – C. 106-109. [Shestakova MV. The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus. Diabetes mellitus. 2010;13(3):106-109. (In Russ).] doi:10.14341/2072-0351-5497
2. Wu T, Rayner CK, Horowitz M. Incretins. In: Herzig S, editor. Metabolic Control. Cham: Springer International Publishing; 2015. p. 137-171. doi:10.1007/164_2015_9
3. Bosi E. Time for Testing Incretin Therapies in Early Type 1 Diabetes? JCEM. 2010;95(6):2607-9. doi:10.1210/jc.2009-2741
4. Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clinical Immunology. 2013;149(3):317-23. doi:10.1016/j.clim.2013.04.006
5. Unger J. Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes. Current Diabetes Reports. 2013;13(5):663-8. doi:10.1007/s11892-013-0404-x
6. Carlsson Å, Sundkvist G, Groop L, Tuomi T. Insulin and Glucagon Secretion in Patients with Slowly Progressing Autoimmune Diabetes (LADA)1. JCEM. 2000;85(1):76-80. doi:10.1210/jcem.85.1.6228
7. Дедов И.И., Шестакова М.В., Кураева Т.Л., и др. Нозологическая гетерогенность, молекулярная генетика и иммунология аутоиммунного сахарного диабета. // Вестник РАМН. – 2015. – Т. 70. – № 2. – С. 132-138. [Dedov II, Shestakova MV, Kuraeva TL, et al. Nozological Heterogeneity, Molecular Genetics and Immunology of Autoimmune Diabetes Mellitus. Annals of the Russian academy of medical sciences. 2015;70(2):132-8. (In Russ).] doi:10.15690/vramn.v70i2.1305
8. Никонова Т.В. Сахарный диабет 1 типа и латентный аутоиммунный диабет взрослых (LADA): клинические, иммуногенетические и гормонально-метаболические аспекты: Дисс. … док. мед. наук, – Москва. 2011. [Nikonova TV. Sakharnyy diabet 1 tipa i latentnyy autoimmunnyy diabet vzroslykh (LADA): klinicheskie, immunogeneticheskie i gormonal'no-metabolicheskie aspekty [dissertation] Moscow; 2011. (In Russ).] Доступно по: http://www.dissercat.com/content/sakharnyi-diabet-1-tipa-i-latentnyi-autoimmunnyi-diabet-vzroslykh-lada-klinicheskie-immuno-g Ссылка активна на 26.06.2016.
9. Redondo MJ. LADA: Time for a New Definition. Diabetes. 2013;62(2):339-40. doi:10.2337/db12-1171.
10. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. Endocrinology. 2003;144(12):5149-58. doi:10.1210/en.2003-0323
11. Issa CM, Azar ST. Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus. Current Diabetes Reports. 2012;12(5):560-7. doi:10.1007/s11892-012-0291-6
12. Lugari R, Dell'Anna C, Ugolotti D, et al. Effect of Nutrient Ingestion on Glucagon-Like Peptide 1 (7-36 Amide) Secretion in Human Type 1 and Type 2 Diabetes. Hormone and Metabolic Research. 2007;32(10):424-8. doi:10.1055/s-2007-978665
13. Vilsbøll T, Krarup T, Sonne J, et al. Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus. JCEM. 2003;88(6):2706-13. doi:10.1210/jc.2002-021873
14. Varga T, Firneisz G, Nagy G, Somogyi A. Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison. Orvosi Hetilap. 2010;151(22):899-902. doi:10.1556/oh.2010.28842
15. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function. Diabetes Care. 2011;34(7):1463-8. doi:10.2337/dc11-0096
16. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, et al. Liraglutide as additional treatment for type 1 diabetes. European Journal of Endocrinology. 2011;165(1):77-84. doi:10.1530/eje-11-0330
17. Kielgast U, Holst JJ, Madsbad S. Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function. Diabetes. 2011;60(5):1599-607. doi:10.2337/db10-1790
18. Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord. 2003;3(1). doi: 10.1186/1472-6823-3-3.
19. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 Diabetes Treatment Beyond Insulin. J Invest Med. 2013;61(1):40-44.
20. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews. 2005;21(2):91-117. doi:10.1002/dmrr.53
Supplementary files
Review
For citations:
Silko I.V., Nikonova T.V., Shestakova M.V. Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin. Obesity and metabolism. 2016;13(2):3-6. (In Russ.) https://doi.org/10.14341/omet201623-6
Views:
3935
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
